Bligh Mathew P, Borgaonkar Joy N, Burrell Steven C, MacDonald David A, Manos Daria
From the Department of Diagnostic Radiology (M.P.B., J.N.B., S.C.B., D.M.) and Division of Hematology, Department of Medicine (D.A.M.), Dalhousie University, Room 307, Victoria Building, 1276 S Park St, Halifax, NS, Canada B3H 2Y9.
Radiographics. 2017 Mar-Apr;37(2):439-461. doi: 10.1148/rg.2017160077.
Non-Hodgkin lymphoma (NHL) frequently manifests in extranodal structures in the chest, often in the form of secondary involvement but occasionally as primary disease. Because staging and treatment are affected by the presence of extranodal disease at imaging, radiologists' interpretation and management of suspicious findings are critical to patient care. Unfortunately, owing to considerable imaging overlap with other diseases, primary extranodal lymphoma is difficult to diagnose with imaging alone. Radiologists should have a heightened degree of suspicion in patients at risk (including patients with immune compromise, autoimmune diseases, or a history of stem cell or solid organ transplant) or with particular imaging appearances (including the vertebral wraparound sign, nonresolving consolidation, an infiltrative soft-tissue mass, and lesions demonstrating vascular encasement without invasion). For patients with known NHL, positron emission tomography/computed tomography (PET/CT) using fluorine 18 (F)-labeled fluorodeoxyglucose (FDG) is now preferred for routine staging in most cases. CT remains heavily used, and identification of subtle extranodal involvement with CT can be improved with use of intravenous contrast material and careful review of multiplanar images. Pericardial effusion, pleural soft tissue (even when mild), mass-like consolidation, perilymphatic nodularity, and new lytic bone lesions are particularly suggestive of secondary involvement in a patient with known NHL. Magnetic resonance imaging is a helpful problem-solving tool when equivocal findings would change staging and treatment. This comprehensive review illustrates the spectrum of CT manifestations of extranodal NHL in the chest, including the pleura, lung, airways, heart, pericardium, esophagus, chest wall, and breast. RSNA, 2017.
非霍奇金淋巴瘤(NHL)常表现于胸部的结外结构,多为继发性累及,但偶尔也为原发性疾病。由于影像学检查发现的结外病变会影响分期和治疗,放射科医生对可疑发现的解读和处理对患者治疗至关重要。不幸的是,由于与其他疾病在影像学上有相当大的重叠,仅靠影像学很难诊断原发性结外淋巴瘤。对于有风险的患者(包括免疫功能低下、自身免疫性疾病患者或有干细胞或实体器官移植史的患者)或有特定影像学表现的患者(包括椎体包绕征、不消散的实变、浸润性软组织肿块以及显示血管包绕但无侵犯的病变),放射科医生应提高警惕。对于已知患有NHL的患者,目前大多数情况下首选使用氟18(F)标记的氟脱氧葡萄糖(FDG)进行正电子发射断层扫描/计算机断层扫描(PET/CT)进行常规分期。CT仍被大量使用,使用静脉造影剂并仔细观察多平面图像可提高CT对细微结外受累的识别能力。心包积液、胸膜软组织(即使很轻微)、肿块样实变、淋巴管周围结节以及新出现的溶骨性骨病变特别提示已知患有NHL的患者有继发性累及。当不明确的发现会改变分期和治疗时,磁共振成像(MRI)是一个有用的解决问题的工具。这篇综述阐述了胸部结外NHL的CT表现谱,包括胸膜、肺、气道、心脏、心包、食管、胸壁和乳腺。RSNA,2017年。